Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.
The authors compared 130 patients treated for cervical dystonia with original botulinum toxin (BTX) type A (Botox; Allergan, Inc., Irvine, CA), 42 of whom were exposed only to the original BTX type A used before 1998 (25 ng protein/100 units), and 119 treated only with the current BTX type A (5 ng of protein/100 units). Blocking antibodies were detected in 4 of 42 (9.5%) patients treated only with original BTX type A but in none of the 119 patients treated exclusively with current BTX type A (p < 0.004). The current preparation decreased the risk of antibody formation by a factor of six. The authors conclude that the low risk of antibody formation after current BTX type A treatment is related to lower protein load.
Jankovic
J
J
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA. josephj@bcm.tmc.edu
Vuong
K D
KD
Ahsan
J
J
D017677:Age Distribution; D019138:Antibodies, Blocking / Q000097:blood; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000276:immunology* / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance / Q000276:immunology; D004356:Drug Storage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D017678:Sex Distribution; D016019:Survival Analysis; D014103:Torticollis / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome
D019138:Antibodies, Blocking; D019274:Botulinum Toxins, Type A